GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Forward PE Ratio

BRAIN Biotech AG (XTER:BNN) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Forward PE Ratio?

BRAIN Biotech AG's Forward PE Ratio for today is 0.00.

BRAIN Biotech AG's PE Ratio without NRI for today is 0.00.

BRAIN Biotech AG's PE Ratio for today is 0.00.


BRAIN Biotech AG Forward PE Ratio Historical Data

The historical data trend for BRAIN Biotech AG's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Forward PE Ratio Chart

BRAIN Biotech AG Annual Data
Trend 2018-05
Forward PE Ratio
294.12

BRAIN Biotech AG Quarterly Data
2018-03
Forward PE Ratio 333.33

Competitive Comparison of BRAIN Biotech AG's Forward PE Ratio

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Forward PE Ratio Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Forward PE Ratio falls into.



BRAIN Biotech AG Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


BRAIN Biotech AG  (XTER:BNN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


BRAIN Biotech AG Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines